News

FDA may ask Novavax to conduct additional trials of its Covid-19 vaccine to receive full approval
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots
There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
Zacks Investment Research on MSN1d
Novavax (NVAX) Flat As Market Gains: What You Should Know
Novavax (NVAX) closed the most recent trading day at $6.41, making no change from the previous trading session. This change lagged the S&P 500's 1.47% gain on the day. At the same time, the Dow added ...
Dermatology Advisor2d
Novavax COVID Vaccine Moves Closer to Full FDA Approval
The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.
Novavax Inc. stock underperforms Thursday when compared to competitors
Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...
Science-Based Medicine4dOpinion
Goodbye to the Novavax Vaccine? Our Flailing Medical Establishment Rejects Medical Freedom and Refuses to Fund Gold-Standard Science.
Our current Medical Establishment doesn't seem to grasp that they are no longer just Fox News and Twitter celebrities who can ...
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot.
Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...
As FDA delays Novavax' COVID vaccine approval, patients fight back
Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...
STAT6d
U.S. health officials inject new uncertainty into approval process for Covid boosters
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.
Novavax says its COVID-19 shot is on track for full FDA approval after delay
WASHINGTON — Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the ...